BRTX BioRestorative Therapies, Inc.
Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1505497 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.5%
TTM net income YoY8.6%
TTM EPS YoY27.9%
Revenue 3-yr CAGR38.4%
Net income 3-yr CAGR—
Margins
Gross margin92.1%
Operating margin-3,975.0%
Net margin-3,089.6%
FCF margin—
EBITDA margin-3,916.2%
Returns
ROE-241.1%
ROA-147.7%
ROIC (approx.)-465.4%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets34.8%
Debt / equity0.00x
Current ratio2.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio10.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $23,170 | $19,600 | $11,800 | $303,300 | $25,000 | $43,300 | $233,600 | $89,100 |
| Cost of revenue | $7,385 | $1,636 | $10,570 | $8,729 | $2,909 | $3,339 | $18,243 | $6,490 |
| Gross profit | $15,785 | $17,964 | $1,230 | $294,571 | $22,091 | $39,961 | $215,357 | $82,610 |
| R&D expense | $1.93M | $2.63M | $2.59M | $2.23M | $2.65M | $1.70M | $1.45M | $1.45M |
| SG&A expense | $1.48M | $1.22M | $1.12M | $1.37M | $2.18M | $1.03M | $1.05M | $1.10M |
| Operating income | -$3.39M | -$3.83M | -$3.71M | -$3.31M | -$4.81M | -$2.69M | -$2.29M | -$2.47M |
| Net income | -$2.15M | -$3.21M | -$3.04M | -$2.66M | -$5.34M | -$1.64M | -$1.09M | -$4.03M |
| EBITDA | -$3.33M | -$3.77M | -$3.66M | -$3.25M | -$4.76M | -$2.64M | -$2.24M | -$2.42M |
| EPS (basic) | -0.12 | — | -0.33 | -0.30 | -0.64 | — | -0.13 | -0.50 |
| EPS (diluted) | -0.12 | — | -0.33 | -0.30 | -0.64 | — | -0.13 | -0.50 |
| Weighted avg. shares (diluted) | 17.73M | — | 9.12M | 8.74M | 8.36M | — | 8.12M | 8.12M |
| Banking | ||||||||
| Net interest income | — | $34,586 | $57,740 | $73,915 | $99,966 | $118,988 | $158,547 | $175,945 |
| Balance sheet | ||||||||
| Cash & equivalents | $3.11M | $1.51M | $602,444 | $1.56M | $1.23M | $547,890 | $1.49M | $2.25M |
| Short-term investments | $479,351 | $1.44M | $3.89M | $5.83M | $7.88M | $10.18M | $11.60M | $12.43M |
| Receivables | $13,300 | $15,500 | $13,400 | $15,000 | $25,000 | $188,400 | $165,000 | $27,400 |
| Current assets | $3.80M | $3.14M | $4.71M | $7.60M | $9.36M | $11.14M | $13.51M | $15.00M |
| PP&E, net | $328,810 | $358,767 | $309,498 | $339,681 | $369,992 | $362,936 | $378,434 | $345,807 |
| Intangibles | $511,761 | $534,198 | $556,634 | $579,071 | $601,508 | $623,945 | $646,381 | $668,818 |
| Total assets | $4.64M | $4.08M | $5.64M | $8.52M | $10.33M | $12.28M | $14.57M | $16.12M |
| Current liabilities | $1.61M | $3.72M | $3.44M | $3.67M | $4.18M | $3.75M | $4.58M | $5.32M |
| Total liabilities | $1.61M | $3.72M | $3.44M | $3.67M | $4.18M | $3.75M | $4.58M | $5.32M |
| Shareholders' equity | $3.03M | $356,744 | $2.21M | $4.85M | $6.14M | $8.53M | $9.99M | $10.80M |
| Shares outstanding | 25.48M | 8.88M | 7.98M | 7.98M | 7.50M | 6.92M | 6.92M | 6.92M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.81M | -$2.42M | -$2.90M | -$2.69M | -$2.78M | -$2.35M | -$1.70M | -$1.87M |
| Capital expenditure | — | $79,669 | $0 | $0 | $36,400 | $12,434 | $58,459 | — |
| Free cash flow | — | -$2.49M | -$2.90M | -$2.69M | -$2.82M | -$2.36M | -$1.76M | — |
| Investing cash flow | $968,447 | $2.40M | $2.00M | $2.13M | $2.37M | $1.53M | $936,753 | $2.97M |
| Financing cash flow | $4.44M | $923,243 | -$49,308 | $888,138 | $1.09M | -$126,316 | $0 | -$12,843 |
| Depreciation & amortization | $52,394 | $52,836 | $52,620 | $52,748 | $51,781 | $50,369 | $48,269 | $47,705 |
| Stock-based compensation | $290,215 | $447,860 | $399,932 | $468,708 | $2.01M | $175,625 | $284,245 | $324,322 |
| Share buybacks | $0 | — | — | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.